Article Details

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT ...

Retrieved on: 2021-04-29 06:00:00

Tags for this article:

Click the tags to see associated articles and topics

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT .... View article details on hiswai:

Excerpt

Under a strategic collaboration, Roche and Atea are jointly developing AT-527 for the treatment of COVID-19. “This pivotal milestone demonstrates a ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up